Companion Pharmacogenetic Study to UMCC 9900/9901

This study has been terminated.
Sponsor:
Information provided by:
University of Michigan Cancer Center
ClinicalTrials.gov Identifier:
NCT00146029
First received: September 1, 2005
Last updated: March 24, 2008
Last verified: March 2008
  Purpose

The purpose is to examine the original breast tumor material to see how much of a metabolizing enzyme (CYP3A4) is present in tumor material. The researchers want to see if this is in any way associated with how the patient responded to docetaxel. They also want to examine the genes in the tumor that are responsible for the production of CYP metabolizing enzymes, to see if they are normal or if they have polymorphisms, or change compared to 'normal' CYP metabolizing enzymes.


Condition
Metastatic Breast Cancer

Study Type: Observational
Study Design: Time Perspective: Retrospective

Resource links provided by NLM:


Further study details as provided by University of Michigan Cancer Center:

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients who participated on UMCC 9900/9901
  • Living patients must give written informed consent

Exclusion Criteria:

  • No tumor block tissue available
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00146029

Locations
United States, Michigan
University of Michigan Cancer Center
Ann Arbor, Michigan, United States, 48109
Sponsors and Collaborators
University of Michigan Cancer Center
Investigators
Principal Investigator: Anne F. Schott, M.D. University of Michigan Cancer Center
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00146029     History of Changes
Other Study ID Numbers: UMCC 3-27
Study First Received: September 1, 2005
Last Updated: March 24, 2008
Health Authority: United States: Institutional Review Board

Keywords provided by University of Michigan Cancer Center:
Patients who participated in UMCC 9900/9901 (Phase II Studies of Tailored-Dose Docetaxel in Metastatic Breast Cancer)

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases

ClinicalTrials.gov processed this record on April 16, 2014